Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer

Phase 1Actinium (²²⁵Ac) rhPSMA-10.1 InjectionPositive

AI Analysis

Summary

Blue Earth Therapeutics announced the first patient has been enrolled in a Phase 1 clinical trial investigating Actinium rhPSMA-10.1 Injection for metastatic castration-resistant prostate cancer. The UCL-sponsored study will evaluate safety, tolerability, and radiation dosimetry of this investigational alpha-emitting PSMA-targeted radiopharmaceutical.

Clinical Trial Data

Phase

Phase 1

Outcome Details

First participant dosed in Phase 1 trial

Importance:5/10

Sentiment:

0.60

Phase 1alpha-emitting radiopharmaceuticalPSMA-targeted therapyprostate cancertrial initiation

Related Companies

$ONT.L $ETST $TRAX $DRTSW

Read the original article

Published by PR Newswire Pharma on July 9, 2026 5:01 AM

Read Original